SCHEMBL4154905

SCHEMBL4154905

CCOC(=O)C1CCCc2c1[nH]c1ccc(Br)cc21

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.77
MEN1 O00255 2/20 0.77
KMT2A Q03164 2/20 0.77
LMNA P02545 2/20 0.77
GAA P10253 1/20 0.75
HTT P42858 1/20 0.75
NPSR1 Q6W5P4 1/20 0.75
SIRT1 Q96EB6 12/20 0.57
KDM4E B2RXH2 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
ALDH1A1 P00352 1/20 0.56
SIRT2 Q8IXJ6 4/20 0.56
RECQL P46063 1/20 0.56
TP53 P04637 1/20 0.53
ALOX15 P16050 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
SIRT3 Q9NTG7 2/20 0.50
DHODH Q02127 1/20 0.50
CYP2D6 P10635 2/20 0.48
KCNH2 Q12809 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2563570 0.93 MAPT (0.66) MAPTMEN1KMT2ALMNAGAA
SCHEMBL16433469 0.87 SIRT1 (0.60) MAPTMEN1KMT2ALMNAGAA
SCHEMBL4725046 0.87 MEN1 (1.00) MAPTMEN1KMT2ALMNAGAA
SCHEMBL16266024 0.87 MAPT (0.77) MAPTMEN1KMT2ALMNAGAA
SCHEMBL31612407 0.87 MEN1 (1.00) MAPTMEN1KMT2ALMNAGAA
SCHEMBL31328292 0.87 MAPT (0.77) MAPTMEN1KMT2ALMNAGAA
SCHEMBL4726687 0.84 MAPT (0.72) MAPTMEN1KMT2ALMNAGAA
SCHEMBL1870436 0.82 SIRT1 (0.73) MAPTMEN1KMT2ALMNAGAA
SCHEMBL4726880 0.82 MEN1 (0.76) MAPTMEN1KMT2ALMNAGAA
SCHEMBL4165081 0.81 SIRT1 (0.75) MEN1KMT2ASIRT1SIRT2RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107739371-B Tetrahydrocarbazole micromolecule organic compound, application thereof in preparing antibacterial drugs and preparation method thereof 华东师范大学 2020-08-25 CN disclosed
US-9271960-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2016-03-01 US disclosed
US-9271960-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2016-03-01 US disclosed
US-9271960-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2016-03-01 US disclosed
US-20150141418-A1 TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL PTC THERAPEUTICS, INC. (US) 2015-05-21 US disclosed
US-20150141418-A1 TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL PTC THERAPEUTICS, INC. (US) 2015-05-21 US disclosed
US-20150141418-A1 TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL PTC THERAPEUTICS, INC. (US) 2015-05-21 US disclosed
US-8946444-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2015-02-03 US disclosed
US-8946444-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2015-02-03 US disclosed
US-8946444-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2015-02-03 US disclosed
EP-1677794-B1 METHODS OF TREATING DISORDER ELIXIR PHARMACEUTICALS INC (US) 2014-12-03 EP disclosed
US-20090042866-A1 Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control PTC THERAPEUTICS, INC. 2009-02-12 US disclosed
US-20090042866-A1 Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control PTC THERAPEUTICS, INC. 2009-02-12 US disclosed
US-20090042866-A1 Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control PTC THERAPEUTICS, INC. 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042866-A1 Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control VEGFA, FLT4, KDR MAPT 2774/4885MEN1 4608/4885KMT2A 3806/4885
US-20150141418-A1 TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL VEGFA, FLT4, KDR MAPT 2774/4885MEN1 4608/4885KMT2A 3806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.